Association of clinicopathologic variables and patient preference with the choice of surgical treatment for early-stage breast cancer: A registry-based study
Emma Söderberg,
Fredrik Wärnberg,
Anna-Karin Wennstig,
Greger Nilsson,
Hans Garmo,
Lars Holmberg,
Carl Blomqvist,
Malin Sund,
Charlotta Wadsten
Affiliations
Emma Söderberg
Department of Surgery, Sundsvall Hospital, Sundsvall, Sweden; Department of Surgical and perioperative Sciences/Surgery, Umeå University, Umeå, Sweden; Corresponding author. Department of Surgery, Sundsvall Hospital, Lasarettsvägen 21, S-856 43, Sundsvall, Sweden.
Fredrik Wärnberg
Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
Anna-Karin Wennstig
Department of Surgical and perioperative Sciences/Surgery, Umeå University, Umeå, Sweden; Department of Oncology, Sundsvall Hospital, Sundsvall, Sweden
Greger Nilsson
Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, University Hospital, Uppsala, Sweden; Department of Oncology, Gävle Hospital, Gävle, Sweden; Department of Oncology, Visby Hospital, Visby, Sweden
Hans Garmo
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
Lars Holmberg
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom
Carl Blomqvist
Department of Oncology, Helsinki University Hospital, Helsinki, Finland
Malin Sund
Department of Surgical and perioperative Sciences/Surgery, Umeå University, Umeå, Sweden; Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Charlotta Wadsten
Department of Surgery, Sundsvall Hospital, Sundsvall, Sweden; Department of Surgical and perioperative Sciences/Surgery, Umeå University, Umeå, Sweden
Introduction: Observational studies suggest that breast conserving surgery (BCS) and radiotherapy (RT) offers superior survival compared to mastectomy. The aim was to compare patient and tumour characteristics in women with invasive breast cancer ≤30 mm treated with either BCS or mastectomy, and to explore the underlying reason for choosing mastectomy. Methods: Women registered with breast cancer ≤30 mm and ≤4 positive axillary lymph nodes in the Swedish National Breast Cancer Register 2013–2016 were included. Logistic regression analyses were performed to assess the association of tumour and patient characteristics with receiving a mastectomy vs. BCS. Results: Of 1860 breast cancers in 1825 women, 1346 were treated by BCS and 514 by mastectomy. Adjuvant RT was given to 1309 women (97.1 %) after BCS and 146 (27.6 %) after mastectomy. Variables associated with receiving a mastectomy vs. BCS included clinical detection (Odds Ratio (OR) 4.15 (95 % Confidence Interval (CI) 3.35–5.14)) and clinical stage (T2 vs. T1 (OR 3.68 (95 % CI 2.90–4.68)), N1 vs. N0 (OR 2.02 (95 % CI 1.38–2.96)). Women receiving mastectomy more often had oestrogen receptor negative, HER2 positive tumours of higher histological grade. The most common reported reason for mastectomy was large or multifocal tumours (53.5 %), followed by patient preference (34.5 %). Conclusion: Choice of surgery is strongly associated with key prognostic factors among women undergoing BCS with RT compared to mastectomy. Failure to control for all relevant confounders may bias results in outcome studies in favour of BCS.
